Skip to content
Congress·In Committee·25 days ago

Compounding Pharmacies: New Safety and Reporting Rules

Also known as: SAFE Drugs Act of 2026

Legislative Progress

✓ Filed
Review
Senate
House
President

Key Points

  • This bill limits how often pharmacies can make 'copycat' versions of drugs that are already sold by major manufacturers. Pharmacies would be restricted to making these copies no more than 20 times a month unless a doctor confirms a specific patient has a unique medical need for a custom version.
  • Pharmacies that ship custom-mixed drugs to patients in other states more than 20 times a month must start filing annual reports with the government. These reports must list exactly what drugs they are making and how many they produce each month.
  • The bill creates stricter rules for 'large-scale' facilities that make more than 100 drug products a year. These businesses would be required to pass a safety inspection before they can start making drugs and must be reinspected at least every two years.
  • To pay for these new safety checks, the bill changes the fees these facilities pay to the government. Instead of a flat $15,000 fee, the government will set a price that covers the full cost of keeping these drug-making sites safe for the public.
  • These changes are designed to make sure pharmacies don't act like mass-production factories without following the same strict safety standards as large drug companies. Most of these new rules would go into effect six months after the bill becomes law.

Milestones

2 milestones2 actions
Feb 5, 2026Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Feb 5, 2026

Introduced in Senate

Related News

5 articles
Indianapolis Business Journal·10 days ago

GLP-1 fight plays out in statehouses, courthouses

U.S. Sens. Jim Banks and Martin Heinrich co-sponsored the SAFE Drugs Act this month to curb mass-production of compounded 'copycat' drugs. The bill clarifies definitions of 'essentially a copy' and sets a monthly limit on units produced by pharmacies without specific medical necessity.

C=
Bloomberg Law·19 days ago

Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding

Novo Nordisk's lawsuit against Hims & Hers marks a new phase in the battle over compounded weight-loss drugs. The legal pressure coincides with the introduction of the SAFE Drugs Act, which aims to tighten federal oversight and restrict the mass-marketing of unapproved drug versions.

CL~
BioWorld·21 days ago

Compounded weight-loss drugs hit on every side

Sens. Banks and Heinrich introduced the SAFE Drugs Act to close loopholes in the FDCA. The bill would limit 503A pharmacies to 20 'essential copies' per month and require large-scale outsourcing facilities to undergo mandatory FDA inspections before starting production.

C=

Source Information

Document Type

Congressional Bill

Official Title

SAFE Drugs Act of 2026

Bill NumberS 3794
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsor

Cosponsors

(1)
D: 1

Analysis generated by AI. While we strive for accuracy, this should not be considered legal or professional advice. Always verify information with official government sources.